Expression of miR-210 in relation to other measures of hypoxia and prediction of benefit from hypoxia modification in patients with bladder cancer

Míreanna comhchosúla

• A gene signature for selecting benefit from hypoxia modification of radiotherapy for high risk bladder cancer patients
  de réir: Yang, L, et al.
  Foilsithe / Cruthaithe: (2017)
• A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer.
  de réir: Eustace, A, et al.
  Foilsithe / Cruthaithe: (2013)
• Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial
  de réir: Eustace, A, et al.
  Foilsithe / Cruthaithe: (2013)
• Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial.
  de réir: Eustace, A, et al.
  Foilsithe / Cruthaithe: (2013)
• Impact of Hypoxia-Induced miR-210 on Pancreatic Cancer
  de réir: Mutian Lian, et al.
  Foilsithe / Cruthaithe: (2023-12-01)